Clinical Trials on BRCA1/2 Mutation in Japan

Total 446 results

Okayama University
Merck Sharp & Dohme LLC

Recruiting

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Breast Cancer | Breast Neoplasms | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | BRCA1 Mutation | BRCA2 Mutation | BRCA Mutation | BRCA-Associated Breast Carcinoma

Japan
AstraZeneca

Completed

To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.

HER2-ve Metastatic Breast Cancer | Germline BRCA1/2 Mutations | Somatic BRCA1/2 Mutations

Italy, Spain, Poland, Taiwan, Canada, France, Germany, Korea, Republic of, Hungary, Japan, Russian Federation, Turkey, United Kingdom, United States, Bulgaria
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.

Active, not recruiting

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (OlympiAD)

Breast Cancer Metastatic | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

Italy, Spain, United States, Czechia, Romania, France, Korea, Republic of, United Kingdom, Hungary, Japan, Peru, Poland, Russian Federation, Turkey, China, Taiwan, Bulgaria, Switzerland, Mexico
Translational Research Center for Medical Innovation...
Okayama University; Japanese Gynecologic Oncology Group (JGOG)

Recruiting

Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2

Fallopian Tube Carcinoma | Peritoneal Carcinoma | Ovarian Carcinoma | BRCA1 and/or BRCA2 Variant Carriers

Japan
Boehringer Ingelheim

Completed

A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive)

Solid Tumors, KRAS Mutation

Japan
Pharming Technologies B.V.
Laboratory Corporation of America; CMIC Co, Ltd. Japan; Axial Biotech, Inc

Recruiting

An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDS

APDS Gene Mutation

Japan
AstraZeneca

No longer available

Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan

PSR Ovarian Cancer With a BRCA Mutation

Japan
Pfizer

Recruiting

Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)

EGFR Mutation-positive Inoperable or Reccrent NSCLC

Japan
Boehringer Ingelheim

Completed

A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS])

Solid Tumors, KRAS Mutation

Japan
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Voretigene Neparvovec in Japanese Patients With Biallelic RPE65 Mutation-associated Retinal Dystrophy

Biallelic RPE65 Mutation-associated Retinal Dystrophy

Japan
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus

Solid Tumor, KRAS Mutation

United States, Taiwan, Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Daiichi Sankyo Co., Ltd.

Completed

Phase 2 Study of DS-8500a in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Takeda

Completed

Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Monotherapy/Combination Therapy With α-GI"

Type 2 Diabetes Mellitus Who Have Been Examined at a Medical Institution

Japan
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

Effects of Miglitol on Daily Plasma Glucose in type2 Diabetes Treated With Insulin

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Monotherapy Study of MP-513 in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)

Type 2 Diabetes Mellitus

Japan
Saitama Medical University

Completed

Relationship Between Body Weight and Glycohemoglobin

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)

Type 2 Diabetes Mellitus

Japan
Takeda

Completed

Alogliptin Tablets Special Drug Use Surveillance: Mild Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Eli Lilly and Company

Completed

A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes

Type 2 Diabetes

Japan
Astellas Pharma Inc

Completed

A Study of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Takeda

Completed

Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Biguanides

Surveillance

Japan
Takeda

Completed

Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Takeda

Completed

Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age"

Type 2 Diabetes Mellitus

Japan
Novartis Pharmaceuticals

Completed

Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes

Type 2 Diabetes

Japan
Hoffmann-La Roche

Terminated

Study on Improvement of Blood Glucose Control in Patients With Diabetes Type 2 Using SMBG

Diabetes

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Japan
Sanofi

Completed

Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure (GAUDI)

Type 2 Diabetes Mellitus

Japan
Niigata Medical Center
Nagaoka Red Cross Hospital

Unknown

Treatment With Sitagliptin in Non-obese Japanese Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes

Japan
Sanofi

Completed

Comparative Study of HOE490 O (Glimepiride and Metformin) Compared With Placebo on Top of Glimepiride

Type 2 Diabetes Mellitus

Japan
Takeda

Completed

Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus"

Type 2 Diabetes Mellitus

Japan
Takeda

Completed

Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Sulfonylurea

Surveillance

Japan
Kyowa Kirin Co., Ltd.

Completed

A Clinical Pharmacology Study of Saxagliptin in Patients With Type 2 Diabetes Mellitus

Diabetes

Japan
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Nagaoka Red Cross Hospital
Kurume University

Unknown

DPP-IV Inhibitors Underlying Mechanism of Cancer in Diabetic Patients

Type 2 Diabetes Mellitus

Japan
Kanazawa University

Unknown

Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases

Type 2 Diabetes Mellitus | Chronic Liver Disease

Japan
Dokkyo Medical University
Merck Sharp & Dohme LLC

Unknown

Effects of Sitaglpitin on Endothelial Function During the OGTT in T2DM

Type 2 Diabetes

Japan
Sanofi

Terminated

Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients on Diet and Exercise (SOLO)

Obesity | Diabetes Mellitus Type 2

Japan
AstraZeneca

Completed

To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients (JMAD)

Type 2 Diabetes

Japan
Sanofi

Completed

Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Daiichi Sankyo Co., Ltd.
Mediscience Planning, Inc.

Completed

A Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus Receiving Sitagliptin

Type 2 Diabetes Mellitus

Japan
Kanagawa Physicians Association
The Japan Kidney Foundation

Completed

Safety and Efficacy of Sitagliptin Added to Insulin Therapy for Type 2 Diabetes (ASSIST-K)

Type 2 Diabetes

Japan
Ono Pharma USA Inc

Completed

Pilot Study of ONO-5129 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
AstraZeneca
Bristol-Myers Squibb

Completed

Drug-drug Interaction Study of Dapagliflozin With Voglibose in Japanese Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

Japan
Sanofi

Terminated

Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-diabetic Drug (SYMPHONY)

Obesity | Diabetes Mellitus Type 2

Japan

3

Subscribe